Actively Recruiting
Hormonal, Metabolic, and Signaling Interactions in PAH
Led by Vanderbilt University Medical Center · Updated on 2025-09-16
1899
Participants Needed
1
Research Sites
1034 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
CONDITIONS
Official Title
Hormonal, Metabolic, and Signaling Interactions in PAH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of idiopathic, heritable, or associated pulmonary arterial hypertension, or family member of affected persons
- Age 0 to 90 years (age 12 to 90 years for skin biopsy in Project 1)
- Reasonable access to clinic for blood collection and testing (Project 2)
- Ability to tolerate fasting before sample collection and endothelial function testing (Project 2)
- Age 7 to 90 years for Project 3
You will not qualify if you...
- Diagnosis other than idiopathic, heritable, or associated pulmonary arterial hypertension
- Age greater than 90 years
- Age less than 12 years or greater than 90 years for skin biopsy in Project 1
- Difficulty accessing clinic for blood collection and testing (Project 2)
- Unable to tolerate fasting state (Project 2)
- Age less than 7 years or greater than 90 years for Project 3
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
Research Team
K
Kelly L Fox
CONTACT
S
Shannon Cordell, BSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here